ASCO: New Advances in Ovarian, Prostate, Lung and Melanoma Treatment


“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased  cancer research from around the world. Some new findings from Dana-Farber researchers included:

  • Joyce Liu, MD

    Joyce Liu, MD, MPH

    Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in a phase 2 clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.. Progression-free survival – the length of time after treatment when the disease doesn’t worsen – was nearly twice as long in patients who received the combined therapy.


  • Christopher Sweeney, MBBS

    Christopher Sweeney, MBBS

    Christopher Sweeney, MBBS, of the Lank Center for Genitourinary Oncology, reported that, in a phase 3 trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment rather than waiting for the disease to become resistant to hormone-blocking agents. The results should change the way physicians have routinely treated such patients since the 1950s, the research team stated.



  • Pasi Janne, MD, PhD

    Pasi A. Janne, MD, PhD

    Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology, presented data from a phase 1 trial showing  that a new, more precisely targeted drug shrank tumors in about half of non-small cell lung cancer patients whose tumors no longer responded to conventional targeted drugs.. The agent, known as AZD9291, also produced markedly fewer side effects than did earlier targeted therapies for this type of cancer.


  • Stephen Hodi, MD

    F. Stephen Hodi, MD

    F. Stephen Hodi, MD, director of the Melanoma Treatment Program, reported that the immunotherapy drug nivolumab continues to have long-term effectiveness against metastatic melanoma, achieving a three-year survival rate of 41 percent in patients participating in a phase 1 trial of the drug. Nivolumab works by unleashing an immune system attack on certain cancer cells.

More information on the Dana-Farber research presented at ASCO.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image


Latest Tweets

Dana-Farber @danafarber
Tips for Lung Cancer Patients: Tips from Dr. Geoffrey Oxnard - #lcsm
Dana-Farber @danafarber
On 12/17 we are discussing how to determine priorities when facing uncertainty about the future. Join us. #DFCIchat
Dana-Farber @danafarber
Dana-Farber researchers call for hospitals to establish bereavement programs for families of deceased patients

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.